"In comparison to small molecule therapeutics and currently available biologics, the logistics management of cell-based material is drastically more complex, requiring ultra-cold temperatures, rigorous quality standards, and coordination between the clinic, biorepository, and manufacturer. Without a comprehensive logistics strategy to manage this and
more, the therapy may never get to the patient."
